Literature DB >> 15949568

In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer.

Ofir Israeli1, Ayala Goldring-Aviram, Shlomit Rienstein, Gilad Ben-Baruch, Jakob Korach, Boleslaow Goldman, Eitan Friedman.   

Abstract

Ovarian cancer, the leading cause of death due to gynecological malignancy, is diagnosed in most cases at an advanced stage. Combined with the paucity of symptoms of early-stage disease, the need to develop novel effective markers for the detection of potentially curable, early-stage disease is self-evident. Comprehensive analyses of somatic gene expression patterns in ovarian cancer were reported previously (n=17) and yielded substantial information on somatically altered genes, information that can potentially be useful in developing early detection markers. To further substantiate the role that these genes play in ovarian cancer tumorogenesis, we surveyed these reports and arranged the significantly altered genes from all reported studies by their chromosomal location (in silico chromosomal clustering). Subsequent comparison of this clustering to known genomic somatic alterations at the DNA level from data obtained using comparative genomic hybridization (CGH) was carried out. The major chromosomal regions that displayed overexpressed genes were correlated with the major CGH-detectable DNA amplification areas at 20q (harboring HE4, SLPI, MYBL2, UBE2C, and SDC4) and 1q (harboring MUC1). These genes may provide insights into ovarian cancer pathogenesis and may also prove to be useful as early detection tools.

Entities:  

Mesh:

Year:  2005        PMID: 15949568     DOI: 10.1016/j.cancergencyto.2004.11.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

1.  A monoclonal antibody against a potential cancer biomarker, human ubiquitin-conjugating enzyme E2.

Authors:  Hongyan Du; Ligang Jie; Weiwen Xu; Yingsong Wu; Tiancai Liu; Ming Li
Journal:  Hybridoma (Larchmt)       Date:  2012-06

2.  The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.

Authors:  Christian Cordes; Robert Häsler; Christian Werner; Tibor Görögh; Christoph Röcken; Lena Hebebrand; W Martin Kast; Markus Hoffmann; Stefan Schreiber; Petra Ambrosch
Journal:  Int J Oncol       Date:  2011-04-14       Impact factor: 5.650

3.  Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Authors:  Adam Clauss; Vivian Ng; Joyce Liu; Huiying Piao; Moises Russo; Natalie Vena; Qing Sheng; Michelle S Hirsch; Tomas Bonome; Ursula Matulonis; Azra H Ligon; Michael J Birrer; Ronny Drapkin
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

4.  Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.

Authors:  Manasa Ramakrishna; Louise H Williams; Samantha E Boyle; Jennifer L Bearfoot; Anita Sridhar; Terence P Speed; Kylie L Gorringe; Ian G Campbell
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

5.  Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.

Authors:  Nabila Rasool; William LaRochelle; Haihong Zhong; Gulshan Ara; Joshua Cohen; Elise C Kohn
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

6.  Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.

Authors:  Nick Devoogdt; Nabila Rasool; Ebony Hoskins; Fiona Simpkins; Nana Tchabo; Elise C Kohn
Journal:  Cancer Sci       Date:  2009-01-14       Impact factor: 6.716

7.  A large scale survey reveals that chromosomal copy-number alterations significantly affect gene modules involved in cancer initiation and progression.

Authors:  Eva Alloza; Fátima Al-Shahrour; Juan C Cigudosa; Joaquín Dopazo
Journal:  BMC Med Genomics       Date:  2011-05-06       Impact factor: 3.063

8.  Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor.

Authors:  Nirmal Chhikara; Mayank Saraswat; Anil Kumar Tomar; Sharmistha Dey; Sarman Singh; Savita Yadav
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

9.  Ovarian cancer: a clinical challenge that needs some basic answers.

Authors:  Kate Lawrenson; Simon A Gayther
Journal:  PLoS Med       Date:  2009-02-03       Impact factor: 11.069

10.  MEIS2 is essential for neuroblastoma cell survival and proliferation by transcriptional control of M-phase progression.

Authors:  Y Zha; Y Xia; J Ding; J-H Choi; L Yang; Z Dong; C Yan; S Huang; H-F Ding
Journal:  Cell Death Dis       Date:  2014-09-11       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.